Contract research organisation hVIVO plc (AIM:HVO) announced on Monday that it has signed an agreement with clinical-stage biotechnology company Inhalon Biopharma Inc to conduct a Respiratory Syncytial Virus (RSV) human challenge trial.

The Phase 2a trial will assess Inhalon's inhaled antiviral candidate, IN-002, using hVIVO's RSV Human Challenge Model. It will evaluate IN-002's safety, pharmacokinetics and antiviral activity at three dose levels.

hVIVO's FluCamp will recruit healthy volunteers for the study. The trial is expected to begin in the second half of 2026 at hVIVO's Canary Wharf facilities.

Revenue from the contract is primarily expected to be recognised in 2026.

IN-002 uses Inhalon's inhaled drug delivery platform.